Demant ASWILYY 94 3-Year ROIIC % is 9.72 as of Dec. 2025, which is 8% below its 10-year median of 10.62. GuruFocus rates WILYY with a GF Score™ of 94/100 and a GF Value™ of $23.74 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Demant AS ranks better than 60.45% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Demant AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 9.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Demant AS's 3-Year ROIIC % or its related term are showing as below:
WILYY's 3-Year ROIIC % is ranked better than 60.45% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs WILYY: 9.72
Demant AS (OTCPK:WILYY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Demant AS 3-Year ROIIC % Related Terms
Demant AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Demant AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Demant AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Demant AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Demant AS (WILYY) has a 3-Year ROIIC % of 9.72 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Demant AS and its competitors. This is near median its historical median of 10.62. According to the industry distribution chart, Demant AS ranks #316 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 39.5%.
Is Demant AS's 3-Year ROIIC % too high?
Demant AS's current 3-Year ROIIC % of 9.72 is near median its 10-year median of 10.62. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.67. Demant AS's value of 9.72 is 482% above this industry median. Based on the distribution chart, Demant AS ranks #316 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Demant AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #316 out of 799 companies for 3-Year ROIIC %. This puts Demant AS in the upper half of its industry. The industry median 3-Year ROIIC % is 1.67. Demant AS's value of 9.72 is 482% above this benchmark. While the company's 10-year median is 10.62 vs. the industry median of 1.67, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current 3-Year ROIIC % of 9.72 is 482% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Demant AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current 3-Year ROIIC % is 9.72, which is near median its own 10-year median of 10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.74, compared to a current price of $20.66 — trading 13% below its estimated fair value. The current 3-Year ROIIC % is 9.72, which is near median its 10-year median of 10.62 and 482% above the Medical Devices & Instruments industry median of 1.67. Demant AS's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Demant AS (WILYY), the current 3-Year ROIIC % is 9.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILYY) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $20.66 is trading 13% below its estimated GF Value™ of $23.74.
GuruFocus considers Demant AS to be Modestly Undervalued.
Key valuation signals for WILYY:
3-Year ROIIC %: 9.72 (near median its 10-year median of 10.62)
GF Value™: $23.74 vs. price of $20.66 (13% below fair value)
Industry Position: 482% above the Medical Devices & Instruments median (#316 of 799)
No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
94GF Score
Get the complete analysis for WILYY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILYY has been successfully added to your 
